Plaque, scalp, nail, & hand & foot psoriasis in adults w/ moderate to severe psoriasis who are candidates for phototherapy or systemic therapy. Active psoriatic arthritis in adults. Palmoplantar pustulosis (PPP) in adults who do not adequately respond to conventional therapy.
SCAdult ≥18 yrPlaque psoriasis, PPP 100 mg at wk 0 & 4, & every 8 wk thereafter. Psoriatic arthritis 100 mg at wk 0 & 4, & every 8 wk thereafter or; 100 mg at wk 0 & every 4 wk thereafter. May be administered alone or in combination w/ conventional synthetic DMARD eg, MTX. Switching from other biologic (ustekinumab or adalimumab therapy) Administer at wk 0 & 4, & every 8 wk thereafter.
View Tremfya overdosage for action to be taken in the event of an overdose.
Special Precautions
Discontinue use if a serious hypersensitivity reaction occurs. May increase risk of infection; not to be given in patients w/ clinically important, active infection. Evaluate patients for Tb prior to treatment; not to be administered in patients w/ active Tb; treat latent Tb prior to treatment. Avoid use of live vaccines. Renal & hepatic impairment. Pregnancy & lactation. Childn <18 yr. Elderly ≥65 yr.
Sign Out
